Celsius double upgraded by Bank of America following strong fourth quarter earnings report

Bank of America upgraded Celsius Holdings (CELH) to Buy from Underperform and raised its price target to $65 from $45 (current levels ~ $53) after upbeat Q4 results and positive CAGNY conference takeaways. The firm lifted its FY2026 adjusted EBITDA forecast to $815.9M from $746M and models fiscal 2026 gross margin at ~50.6%, citing expected 17% shelf-space gains for core Celsius NA and stronger-than-expected Alani Nu topline trends; analysts flagged inventory swings between brands as the primary downside. Investors should note the upgrade is valuation-driven but reflects improved consumption and category momentum, which could support further re-rating if trends persist.

Analysis

Market structure: BofA’s upgrade makes CELH a direct beneficiary of re-rating risk; expect incremental shelf-share gains (BofA cites +17% NA shelf space in 2026) to translate to mid-single-digit market-share shifts versus smaller competitors and incremental gross-margin leverage (modeled ~50.6% FY26). Retailers benefit from stronger turnover but temporary inventory rebalancing between Celsius core and Alani Nu could compress retailer ordering volatility. Cross-asset: equity implied vol should compress after the upgrade (short-term), negligible macro FX or commodity impact beyond small sugar/packaging input sensitivity; credit markets unlikely to move absent wider consumer staples stress.

Risk assessment: Tail risks include regulatory scrutiny of energy drinks (labeling/caffeine limits), sharper-than-expected inventory destocking, or promotional margin erosion that could knock adjusted EBITDA below guidance (~$816m). Time horizons: immediate (days) = price pop and vol compression; short-term (4–12 weeks) = scanner/Nielsen confirmation of sustained Alani Nu trends; long-term (3–12 months) = consumption stability and margin persistence. Hidden dependencies: slotting fees, retailer promotional cadence, and cannibalization between Celsius brands are second-order risks that can flip comps quickly. Catalysts: next 4 weekly scanner reads, Q1 rev cadence, and retail restock signals.

Trade implications: Direct play: establish a 2–3% long position in CELH (~$53) targeting $65 in 6–12 months with a stop-loss ~ $45 (~15% downside). Options: buy a 9–12 month 55/70 call vertical to limit capital at risk, or sell 60-day cash-secured $48 puts to collect premium and set a lower-cost entry. Pair trade: long CELH / short MNST (size 1:0.5) over 6–12 months to capture re-rating vs. incumbent scale. Sector tilt: rotate 1–2% from KO into high-growth non-alc beverages (CELH) to raise portfolio growth exposure.

Contrarian angles: The upgrade is partly valuation-driven — upside (~22% to $65) may already be baked into CELH’s current ~$53 price; investor focus may underappreciate inventory-driven near-term margin volatility and tougher H2 comps. Historical parallels (rapid retail expansion in energy drinks) show rebounds can be followed by promotional troughs that compress gross margins for 1–3 quarters. If upcoming scanner data disappoints over two consecutive weeks or EBITDA trends miss by >5%, re-rating can reverse sharply; conversely, sustained scanner outperformance would make CELH a strong re-rating candidate versus MNST/KO.

Key Decisions for Investors

• Establish a 2–3% long position in CELH (buy shares near $50–$56) with a target of $65 within 6–12 months and a hard stop-loss at ~$45 (≈15% downside), position size to be cash-weighted.
• Implement a defined-risk options trade: buy a 9–12 month CELH 55/70 call vertical (limits max loss) sized to equal no more than 1% portfolio risk; if premium is cheap, consider a 60-day roll to capture continued scanner confirmation.
• Sell cash-secured CELH $48 puts expiring in ~60 days to collect premium and potentially enter at ~10% discount to current levels; close or roll if CELH prints two consecutive weekly scanner misses.
• Run a relative-value pair: long CELH / short MNST at a 1:0.5 dollar ratio for 6–12 months to express re-rating potential vs. incumbent; trim if CELH outperforms by >25% or MNST outperforms by >10%.
• Monitor IRI/Nielsen weekly scanner data and retailer restock/slotting announcements for the next 4–8 weeks; if Alani Nu scanner trends fall >5% week-over-week for two consecutive weeks, reduce CELH exposure by 50%.